脂质体布比卡因对比持续神经阻滞:脂质体布比卡因可能非劣效且更具成本效益
该回顾性研究纳入2015至2020年单中心23名骨科医生施行的初次全膝关节置换术患者2378例,其中1640例接受脂质体布比卡因、738例接受疼痛泵持续神经阻滞。结果显示两组在术后第0、1、2、3天疼痛评分、30天和90天再入院率、急诊就诊率、吗啡毫克当量使用量及平均住院时长上均无显著差异,脂质体布比卡因估计每例节省95美元,研究期间共节省155800美元。
要点
- 脂质体布比卡因与疼痛泵持续神经阻滞在术后疼痛评分、再入院、急诊就诊及住院时长上无显著差异。
- 脂质体布比卡因组估计每例节省95美元,研究期间共节省155800美元。
- 两组在30天和90天再入院率、急诊就诊率、吗啡毫克当量使用量上均无显著差异。
核心结论
- 脂质体布比卡因不劣于疼痛泵持续神经阻滞,且过渡至该药物与成本节省相关。
研究设计与样本
- 回顾性病历审查,纳入2015至2020年单中心23名骨科医生施行的初次全膝关节置换术患者,符合标准者2378例,其中脂质体布比卡因组1640例、疼痛泵组738例。
主要发现
- 术后第0、1、2、3天疼痛评分组间无显著差异(P值分别为0.77、0.86、0.08、0.40)。
- 30天和90天再入院率组间无显著差异(P值分别为0.527和0.374)。
- 30天和90天急诊就诊率组间无显著差异(P值分别为0.129和0.108)。
- 吗啡毫克当量使用量组间无显著差异(P=0.194),平均住院时长组间无显著差异(P=0.348)。
- 估计每例患者节省95美元,研究期间共节省155800美元。
关键数值与推荐
- 纳入标准为接受脂质体布比卡因或疼痛泵治疗,排除标准为同时接受两种麻醉药物及翻修手术。
- 两组人口学差异无统计学意义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Regional anesthesia with adductor canal block has become the standard of care for pain management after total knee arthroplasty (TKA). We hypothesized that liposomal bupivacaine (LB) may be noninferior to continuous nerve block with a pain pump in terms of average pain scores, 30- and 90-day readmissions, and emergency department (ED) visits while reducing cost. METHODS: A retrospective chart review was performed on primary TKA patients from 2015 to 2020 by 23 orthopaedic surgeons at a single institution. The inclusion criteria was treatment with LB or a pain pump, and exclusion criteria was receipt of both anesthetics and revision surgery. A total of 2,378 patients met the inclusion criteria with 1,640 patients treated with LB and 738 treated with the pain pump. Demographic differences were not statistically significant. Primary outcomes were average pain scores, 30- and 90-day readmissions, and ED visits. Secondary outcomes were average milligram morphine equivalents per admission, hospital lengths of stay , and costs. RESULTS: There was no significant difference in pain scores on postoperative days 0, 1, 2, or 3 (P = .77, .86, 0.08, and 0.40, respectively), 30- or 90- day readmissions (P = .527 and P = .374), ED visits (P = .129 and P = .108), milligram morphine equivalents utilizations (P = .194), or average hospital LOS (P = .348). We estimated a potential cost savings of $95 per patient and $155,800 over the course of the study. CONCLUSION: LB was found to be noninferior to a pain pump, and the transition to this medication was associated with cost savings.
引用
- Lonza GC, Yuan F, Pham FM, et al. Liposomal Bupivacaine Versus Continuous Nerve Block: Liposomal Bupivacaine May be Non-inferior and More Cost Effective. J Arthroplasty. 2022. PMID: 36529199. doi:10.1016/j.arth.2022.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。